FIBROSARCOMA DRUGS MARKET ANALYSIS

Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming connective tissue called as fibroblasts. Although, this condition can occur at any age, it is commonly diagnosed between the age of 30-60 years. Patients suffering from genetic conditions such as retinoblastoma, nevoid basal cell carcinoma syndrome are more prone to develop fibrosarcoma. However, precise cause of disease is unknown. Furthermore, individuals undergoing radiation therapy or having lymphedema or get exposed to chemicals such as thorium dioxide vinyl chloride or arsenic are more prone to fibrosarcoma. This disease is symptomized by muscular pain, which increases exponentially with time. It is diagnosed by bone lesions in radiograph, followed by advanced imaging and laboratory test and confirmed by biopsy results. Treatment of the disease depends on the stage of tumour during diagnosis. Surgery and radiation therapy are the treatment used for fibrosarcoma.  Currently, limited number of treatment methods and various side effects of chemotherapy such as hair loss or low blood platelet count are propelling demand for research and development activities in fibrosarcoma treatment.

Fibrosarcoma Drugs Market Taxonomy:

By Type:

• Adult Fibrosarcoma
• Infantile Fibrosarcoma

By Active Ingredient:

• Doxorubicin Hydrocholride
• Ifosfamide
• Dacarbazine
• Pazopanib Hydrochloride
• Other Active Ingredient

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies

Fibrosarcoma Drugs Market Driver

Increasing research activities are expected to fuel the growth of fibrosarcoma drugs market over the forecast period. Fibrosarcoma being malignant tumor requires early removal through complete eradication of malignant cells by chemotherapy. Currently available chemotherapy includes side-effects such as acquirance of multi-drug resistance (MDR), severe side-effects and high rate of reoccurrence, which in turn demands for safer drug for chemotherapy. For instance, Loxo Oncology Inc., 2017, received US FDA approval for investigational new drug application for LOXO 195, a next-generation TRK inhibitor for treatment of patients with cancers that have acquired resistance to initial TRK therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced partnership with Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel drug combination studies, clinical trial for targeted drug delivery and genetic profile based medication are expected to boost growth of the fibrosarcoma drugs market over the forecast period.

Increasing prevalence of fibrosarcoma is expected to augment growth of the fibrosarcoma drugs market. According to American Society of Clinical Oncology, 2017, around 3260 individuals were diagnosed by primary bone cancer in U.S. out of which 4% of adults are suffering from fibrosarcoma and prevalence of the disease is higher in men than in women. Currently, diagnosis facility lacks in early and accurate detection of fibrosarcoma. Therefore, rising awareness for disease and advancement in diagnostic as well as therapeutic procedures are expected to propel growth of the fibrosarcoma drugs market. Furthermore, companies, universities, and institutes are taking initiatives to provide inexpensive, readily available drugs with less side-effects as compared to present drugs that will help key players to strengthen product portfolio, in turn driving growth of the fibrosarcoma drug market. Key players as well as government organization such as Nation Cancer Institute or American Society of Clinical Oncology sponsors or collaborate for the development of novel therapies and drugs. For instance, Bayer partners with loxo oncology to develop and commercialise cancer therapies. Furthermore, Bristol-Myers Squibb Company acquired IFM therapeutics, 2017, to acquire right on preclinical stimulator of interferon genes (STING) and NLRP3 agonist programs, which are focused on enhancing the innate immune response for tumour.

Fibrosarcoma Drugs Market- Regional Analysis

The global fibrosarcoma market is projected to hold dominant position in North America over the forecast period, due to increasing research activities leading to better fibrosarcoma treatment. Furthermore, well-developed healthcare infrastructure is fuelling growth of fibrosarcoma market. Asia Pacific is expected to be fastest growing market over the forecast period due to developing healthcare infrastructure and rising awareness regarding conditions of fibrosarcoma.

Fibrosarcoma Drugs Market- Competitor

Major players operating in fibrosarcoma drugs market include Cadila Healthcare Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter International Inc., Eli Lilly and Company, Pfizer limited, Johnson & Johnson., and Celon Laboratories Pvt. Ltd.